G1GLP1 Note Applies to All countries

HomeGenericsGLP-1

GenericAll countries · Checked

Generic GLP-1 Drugs: Which Generic Weight Loss Injections Exist

As of November 20, 2026, generics exist for two GLP-1 ingredients. Liraglutide has weight loss generics in the US and the UK. Semaglutide has weight management generics in Canada (Sevmia) and India (Noveltreat and Alkem), while Brazil's pens are for diabetes and Anvisa does not call them generics.

Is there a generic GLP-1 for weight loss?

Yes. Liraglutide in the US and UK, and semaglutide in Canada and India. Tirzepatide has none yet.

Generic availableLiraglutide, daily injection

Weight loss generic on saleUS, UK

Semaglutide generic for weight managementCanada, India

Brazil semaglutide pens (diabetes)Not called generics by Anvisa

Based on the FDA, the European Medicines Agency, Anvisa in Brazil, Health Canada and company releases.

Even with a generic, the price depends on where you live.

See the cheapest GLP-1 options in the US

In the UK? See weight loss injection prices in the UK.

What generic meansListLiraglutideWeight lossSemaglutideTirzepatideWhenCanada and IndiaNowFAQ

What a generic GLP-1 is

A generic is a medicine approved as the same as the brand: the same active ingredient, the same strength and the same way of taking it. Only the name and the maker differ.

GLP-1 medicines are injections, so the generics are injection pens too. The pen itself can look different from the brand pen.

A generic needs the ingredient patent to have ended. Even then, a regulator must approve each product before it goes on sale.

Generic GLP-1 drugs list

Brand and generic status by ingredient

Liraglutide (Saxenda, Victoza)Generics on sale

Semaglutide (Wegovy, Ozempic, Rybelsus)Generics in Canada and India, not in Brazil

Tirzepatide (Mounjaro, Zepbound)No generic

The next sections go through each one.

Generic liraglutide

Liraglutide is the GLP-1 whose patents have run out. Novo Nordisk lists the Saxenda and Victoza patents as expired in the US, China, Japan and Europe.

In the US, the FDA approved Hikma's generic Victoza on December 23, 2024. It is a daily injection for type 2 diabetes in adults and in children aged 10 and over.

For weight loss, Teva announced FDA approval and launch of generic Saxenda on August 28, 2025. It is the first generic GLP-1 indicated for weight loss.

It is approved for adults with obesity, or with excess weight and a weight-related condition, and for ages 12 to 17 who weigh more than 60 kg and have obesity.

More on names and brands is in generic liraglutide and Saxenda.

Generic weight loss injection

In the UK, Biocon launched Biolide, its generic Saxenda for chronic weight management, on February 28, 2025, after approval from the MHRA. Its diabetes version is Liraglutide Biocon.

In the European Union, Ablymico was authorised on July 15, 2026. It is a liraglutide hybrid medicine that uses Saxenda as its reference and differs in how the ingredient is made.

In Brazil, Anvisa approved two liraglutide pens for obesity on October 29, 2026, Lyrza and Wylovol, both made by Biocon in India.

A generic still needs a prescription, and your prescriber chooses the product.

Generic semaglutide

Generic semaglutide exists in Canada and India, and it includes versions for weight management.

Semaglutide approvals by country

India, March 21, 2026Noveltreat and Alkem for weight management, Obeda for diabetes

Canada, April 28 and June 29, 2026Dr. Reddy's for diabetes, Sevmia for weight management

Brazil, May 26 and October 29, 2026Diabetes pens, not called generics by Anvisa

Health Canada describes Apotex's Sevmia as a generic of Wegovy for chronic weight management in ages 12 and over. It gave no launch date or price.

Brazil's Anvisa registered Ozivy, Embeltah and Sevema as synthetic semaglutide pens and does not call them generics. All three are for diabetes.

The full list by country is in generic semaglutide.

Generic tirzepatide

Tirzepatide, the ingredient in Mounjaro and Zepbound, has no generic in any of the countries above.

The latest is kept in Mounjaro generic name and generic tirzepatide.

When generic Wegovy and Ozempic will arrive

Novo Nordisk lists the semaglutide ingredient patent as ending in 2032 in the US, 2031 in Europe and 2031 in Japan. For China the year is 2026.

US2032Europe2031Japan2031

The European year is based on Germany, and each country differs. In the US and Europe, generic Wegovy and Ozempic are years away.

Brand-by-brand answers are in Wegovy generic name and generic Ozempic.

Generic GLP-1 in Canada and India

Canada approved Dr. Reddy's generic semaglutide on April 28, 2026, a weekly injection for adults with type 2 diabetes. On June 29, 2026 it approved Sevmia for weight management, with no launch date given. Apotex's generic of Ozempic launched in May, and BC PharmaCare listed two Ozempic generics on June 15, 2026.

In India, Dr. Reddy's launched Obeda for diabetes on March 21, 2026, at INR 4,200 a month for the 2 mg or the 4 mg pen. The same day Sun Pharma launched Noveltreat for adult weight management, and Alkem launched products for diabetes and weight management from INR 1,800 a month.

Indian prices for every GLP-1 are in weight loss injection price in India.

What to do now

If you already take a GLP-1, ask your prescriber whether a generic exists where you live. Do not change product or dose on your own.

If cost is the worry in the US, start with insurance and manufacturer programs in GLP-1 without insurance.

In the UK, the NHS rules are in weight loss injections on the NHS.

Medicines still being developed are in new weight loss drugs.

Generic GLP-1 FAQ

Is there a generic GLP-1 for weight loss?

Yes. In the US it is Teva's generic Saxenda, in the UK Biolide, in Canada Sevmia and in India Noveltreat.

Is generic semaglutide approved for weight loss?

In some countries, yes. Sevmia in Canada and Noveltreat and Alkem's products in India are for weight management. Brazil's pens are for diabetes and Anvisa does not call them generics.

When will generic Wegovy be available?

In the US the ingredient patent runs to 2032, and no launch date is set.

Is there a generic tirzepatide?

No. Mounjaro and Zepbound have no generic.

Is generic Saxenda the same medicine as Saxenda?

Yes, the ingredient and the approved use are the same. The name, maker and pen design can differ.

Keep reading

Generic Saxenda (liraglutide)

Generic semaglutide

Wegovy generic name

Generic Ozempic

GLP-1 cost 2026

GLP-1 drugs explained

This page follows regulator announcements and company releases, and it is updated when a status changes. See how we check our pages.

Update log

: First published.

Sources

FDA approves first generic of once-daily GLP-1 injection for type 2 diabetes (FDA, December 23, 2024).

Teva announces FDA approval and launch of generic Saxenda (Teva, August 28, 2025).

Biocon launches liraglutide in the United Kingdom (Biocon, February 28, 2025).

Ablymico (European Medicines Agency).

Canada becomes the first G7 country to approve a generic version of semaglutide (Health Canada, April 28, 2026).

Canada approves first generic semaglutide for weight loss (Health Canada, June 29, 2026).

Sun Pharma semaglutide launch in India (Sun Pharma, March 21, 2026).

Dr. Reddy's launches Obeda semaglutide injection in India (Dr. Reddy's Laboratories, March 21, 2026).

Anvisa approves five new GLP-1 pens (Anvisa, Brazil, October 29, 2026).

Novo Nordisk Annual Report 2025, commercial execution (patent expiry table).

GLP1 Note is an independent information site. Which product you use is decided by your prescriber.